Kimberly-Clark (NASDAQ:KMB) is making a massive bet but investors aren't sure on how to feel about it. The maker of Kleenex ...

US consumer health company Kimberly-Clark has agreed to acquire Johnson & Johnson (J&J) consumer health spinout Kenvue for ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

Consumer giant Kimberly-Clark has agreed to buy Kenvue, the parent company of embattled brand Tylenol, for nearly $49 billion. But what does this mean for consumers and shareholders?

Under the agreement, each Kenvue Inc. (NYSE:KVUE) shareholder would receive $3.5 per share in cash as well as 0.14625 ...

While the canard that many mergers fail to provide a return to shareholders does not appear to be supported by the data, mergers still occur that appear to be motivated by little more than a CEO& ...

Kimberly-Clark is buying Tylenol maker Kenvue in a cash and stock deal worth about $48.7 billion, creating a huge consumer ...

Palantir Technologies, which came into the day with a stunning 165% gain for the year so far, rose another 3.3%. Traders ...

The consumer health and wellness giants are both Dividend Kings, with more than 50 years of consecutive annual payout ...

As equity markets face sustained volatility, investors are actively seeking high-quality assets that can withstand economic ...

Kimberly-Clark is buying Tylenol maker Kenvue in a cash and stock deal worth about $48.7 billion, creating a massive consumer health goods company. Shareholders of Kimberly-Clark will own about 54% of ...